AAM Laments Price Negotiation Legislation Passing US Senate
‘Flawed’ Law Will ‘Further Frustrate Access’ To Generics And Biosimilars
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
